Furoscix is a drug owned by Scpharmaceuticals Inc. It is protected by 4 US drug patents filed from 2022 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 03, 2034. Details of Furoscix's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12370168 | NA |
Apr, 2034
(8 years from now) | Active |
| US10272064 | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(8 years from now) | Active |
| US11433044 | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(8 years from now) | Active |
| US9884039 | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Furoscix's patents.
Latest Legal Activities on Furoscix's Patents
Given below is the list of recent legal activities going on the following patents of Furoscix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification
Critical | 21 Jan, 2023 | US9884039 |
| Mail Certificate of Correction Memo | 20 Jan, 2023 | US9884039 |
| Certificate of Correction Memo | 18 Jan, 2023 | US9884039 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 31 Oct, 2022 | US10272064 |
| Patent Issue Date Used in PTA Calculation
Critical | 06 Sep, 2022 | US11433044 |
| Recordation of Patent Grant Mailed
Critical | 06 Sep, 2022 | US11433044 |
| Email Notification
Critical | 18 Aug, 2022 | US11433044 |
| Issue Notification Mailed
Critical | 17 Aug, 2022 | US11433044 |
| Dispatch to FDC | 28 Jul, 2022 | US11433044 |
| Application Is Considered Ready for Issue
Critical | 28 Jul, 2022 | US11433044 |
FDA has granted several exclusivities to Furoscix. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Furoscix, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Furoscix.
Exclusivity Information
Furoscix holds 1 exclusivities. All of its exclusivities have expired in 2025. Details of Furoscix's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2025 |
US patents provide insights into the exclusivity only within the United States, but
Furoscix is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Furoscix's family patents as well as insights into
ongoing legal events
on those patents.
Furoscix's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Furoscix's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 03, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Furoscix Generic API suppliers:
Furosemide is the generic name for the brand Furoscix. 31 different companies have already filed for the generic of Furoscix, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Furoscix's generic
About Furoscix
Furoscix is a drug owned by Scpharmaceuticals Inc. It is used for treating congestion due to fluid overload in adults with NYHA class II/III chronic heart failure. Furoscix uses Furosemide as an active ingredient. Furoscix was launched by Scpharmaceuticals in 2022.
Approval Date:
Furoscix was approved by FDA for market use on 07 October, 2022.
Active Ingredient:
Furoscix uses Furosemide as the active ingredient. Check out other Drugs and Companies using Furosemide ingredient
Treatment:
Furoscix is used for treating congestion due to fluid overload in adults with NYHA class II/III chronic heart failure.
Dosage:
Furoscix is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG/10ML (8MG/ML) | SOLUTION | Prescription | SUBCUTANEOUS |